Outlook Therapeutics (OTLK) Operating Expenses (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Operating Expenses of -$9.6 million for Q1 2026, down 128.19% year-over-year from $34.0 million in Q1 2025, and down 178.18% quarter-over-quarter from $12.2 million in Q4 2025.
Outlook Therapeutics (OTLK) Operating Expenses (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Operating Expenses for 12 consecutive years, with -$9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 128.19% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at $35.8 million (up 19.43% YoY), while the FY2025 annual figure was -$3.1 million, down 184.27% from the prior year.
- Operating Expenses eased to -$9.6 million in Q1 2026 per OTLK's latest filing, from $12.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $34.0 million in Q1 2025 and bottomed at -$45.2 million in Q3 2024.
- Historically, Operating Expenses has averaged $11.7 million across 5 years, with a median of $16.3 million in 2025.
- On a YoY basis, Operating Expenses climbed as much as 176.98% in 2024 and fell as far as 462.51% in 2024.
- Outlook Therapeutics' Operating Expenses stood at $15.7 million in 2022, then plunged by 34.2% to $10.3 million in 2023, then jumped by 109.31% to $21.6 million in 2024, then tumbled by 43.32% to $12.2 million in 2025, then sank by 178.18% to -$9.6 million in 2026.
- Business Quant data shows OTLK's Operating Expenses at -$9.6 million in Q1 2026, $12.2 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | 9.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.57 Mn |
| Dec 31, 2025 | 12.25 Mn |
| Sep 30, 2025 | 16.31 Mn |
| Jun 30, 2025 | 16.81 Mn |
| Mar 31, 2025 | 33.97 Mn |
| Dec 31, 2024 | 21.61 Mn |
| Sep 30, 2024 | -45.17 Mn |
| Jun 30, 2024 | 19.56 Mn |
| Mar 31, 2024 | 18.94 Mn |
| Dec 31, 2023 | 10.32 Mn |
| Sep 30, 2023 | 12.46 Mn |
| Jun 30, 2023 | 18.14 Mn |
| Mar 31, 2023 | 6.84 Mn |
| Dec 31, 2022 | 15.69 Mn |
| Sep 30, 2022 | 13.99 Mn |
| Jun 30, 2022 | 17.02 Mn |
| Mar 31, 2022 | 18.91 Mn |
| Dec 31, 2021 | 13.15 Mn |
| Sep 30, 2021 | 13.44 Mn |
| Jun 30, 2021 | 11.47 Mn |